Latest Financial Position News

Little Green Pharma Ltd reported a 9.6% revenue increase to $19.2 million and slashed its net loss by 73% in the half-year ending September 2025, driven by strong growth in European medicinal cannabis markets.

Golden State Mining has completed a $1.5 million placement at 0.8 cents per share, appointed Keith Middleton as Managing Director, and launched a strategic review of its gold projects in Western Australia.

Eagle Mountain Mining Limited has lodged a prospectus for a non-renounceable entitlement offer to raise up to A$1.98 million, supporting exploration and development of its copper-gold projects in Arizona, USA. The offer includes attaching options and follows a recent $1.66 million placement.

ReadCloud Limited reported a robust FY25 with a 109% surge in underlying EBITDA, driven by strong growth in its Australian school businesses. The company’s FY26 outlook targets continued organic expansion and disciplined execution amid industry funding uncertainties.

Tinybeans Group launches a partially underwritten entitlement offer to fund the integration of its recent acquisition Qeepsake, aiming to boost product innovation and subscriber growth.

Cann Group Limited has successfully raised an additional $2.5 million through a Share Purchase Plan and shortfall placement, complementing a prior $6.5 million institutional placement. These funds will primarily support debt repayment and strengthen the company’s financial position.

Ava Risk Group announces the upcoming retirement of CEO Mal Maginnis, with senior executive Neville Joyce appointed as Acting CEO. The company embarks on a global search for a permanent replacement amid strong recent growth.

Lake Resources N.L. reports significant progress on its Kachi lithium project, unveiling enhanced project economics and next-generation lithium extraction technology amid a bullish lithium market and supportive Argentine political climate.

Worley Limited reported solid financial results for FY2025, highlighted by disciplined capital management including a $269 million share buy-back and a strong focus on sustainability. The company outlined strategic priorities and anticipates moderate growth in FY2026 with a new growth strategy to be revealed next year.

AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.

Bio-Gene Technology Limited updates on its development of two novel insecticides, Flavocide and Qcide, highlighting regulatory progress, commercial partnerships, and a strong market outlook across multiple sectors.